UBS Group
PACB icon

UBS Group’s Pacific Biosciences PACB Stock Holding History

UBS Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-749,100
Closed -$8.67M – 9450
2023
Q1 		$8.67M Buy
+749,100
New +$7.45M ﹤0.01% 1996

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group's PACB Position: Q1 2026 in Review

UBS Group reduced its Pacific Biosciences (PACB) stake by 48% in Q1 2026, selling an estimated $2.74M and leaving 1,640,099 shares worth $2.16M. The position accounts for ﹤0.01% of the portfolio, ranked #4899.

UBS Group first reported a position in PACB in Q4 2014 and has held it in 46 quarters since. The position peaked at $22.1M in Q4 2016. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • UBS Group held 1,640,099 shares of Pacific Biosciences worth $2.16M as of Q1 2026.
  • UBS Group sold 1,531,447 Pacific Biosciences shares in Q1 2026, an estimated $2.74M.
  • Pacific Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4899 holding.
  • UBS Group first reported a position in Pacific Biosciences in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Pacific Biosciences position peaked at $22.1M in Q4 2016.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.